Background: This study aimed to determine whether patients with lower abdominal symptoms can be investigated quickly using results of faecal haemoglobin concentration (f-Hb) measurements, and whether this test could form part of a diagnostic pathway for significant colorectal disease.
Methods: Nine hundred and nine consecutive patients referred from primary care for colonoscopy were invited: 507 submitted samples for f-Hb measurement with a quantitative faecal immunochemical test for haemoglobin (FIT) (HM-JACKarc, Kyowa-Medex, Japan) and a diagnostic colonoscopy was completed in 484 patients.
Results: Colorectal cancer (CRC), higher risk adenoma (HRA), inflammatory bowel disease (IBD) and/or colitis was found in 45 patients (9.3%); these had significantly higher (p<0.0001) f-Hb than the group of 243 with normal colonoscopy plus the 196 patients with less significant clinical findings. The 11 (2.2%) patients with CRC all had f-Hb >190 μg Hb/g faeces. Using a f-Hb cut-off of 10 μg Hb/g faeces, for the group with CRC or HRA or IBD or colitis, sensitivity was 68.9%, specificity 80.2%, positive predictive value (PPV) 26.3% and negative predictive value (NPV) 96.2%. Sensitivity and NPV were 100% for CRC suggesting f-Hb is a good rule-in test for CRC. Of the 243 patients with normal colonoscopy, 81.2% had f-Hb<10 μg Hb/g faeces.
Conclusions: The high NPV for significant colorectal diseases suggests that f-Hb could be used as a rule-out test in this context. Potential exists for using f-Hb measurements to investigate symptomatic patients and guide the use of colonoscopy resources: detailed algorithms for the introduction of f-Hb measurements requires further exploration.
Pauline Warnock and the staff of the NHS Lanarkshire Patient Centred Booking Service are thanked the distribution of the FIT devices and patient information. Professor Chris Robertson at the University of Strathclyde is thanked for his initial review of the data. Kyowa-Medex Co., Ltd, Tokyo, Japan, and Alpha Laboratories Ltd, Eastleigh, UK, are thanked for providing the loan of the analyser, all training and reagents, calibrators, controls and consumables. Yasunobu Masuda, Matthew Davis and Mairi White are thanked for their considerable help in the logistics required, for the loan of the automated analytical system and for their ongoing interest throughout the study.
Author contributions: The study was conceived by IMG, CGF and HBY. All authors participated in the design of the study, participated in data collection and analysis, commented on the implications of the results, and critically reviewed the final manuscript. LT performed the analytical testing and LM reviewed the endoscopy findings. IMG, CGF and HBY performed the data analysis and wrote the initial drafts of the manuscript. IMG is guarantor.
Ethical approval: The study was approved by the West of Scotland ethics service in February 2013 – reference 13/WS/0031.
Research funding: This research was supported, by NHS Lanarkshire; the analyser, training, reagents, calibrators, controls and consumables were fully supported by Kyowa-Medex Co., Ltd, Tokyo, Japan, and Alpha Laboratories Ltd, Eastleigh, Hants, UK.
Employment or leadership: None declared.
Competing interests: CGF has consultancy contracts with Kyowa-Medex Co., Ltd, Mode Diagnostic, Glasgow, Scotland, and Immunostics Inc., Ocean, NJ, USA, and received travel support from Alpha Labs Ltd; all other authors have no other relationships or activities that could appear to have influenced the submitted work. The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. Bowelcanceruk. Diagnosing bowel cancer early: right test, right time, 2014 Available at: http://www.bowelcanceruk.org.uk/campaigns-policy/latest-campaigns/right-test,-right-time/read-our-report/. Accessed: 28 June 2015.Search in Google Scholar
5. National Institute for Health and Care Excellence. NICE NG12. Recognition and referal. NICE: London, 2015 Available at: http://www.nice.org.uk/guidance/ng12. Accessed:28 June 2015.Search in Google Scholar
6. Oono Y, Iriguchi Y, Doi Y, Tomino Y, Kishi D, Oda J, et al. A retrospective study of immunochemical fecal blood testing for colorectal cancer detection. Clin Chim Acta 2010;411:802–5.10.1016/j.cca.2010.02.057Search in Google Scholar
7. Allison JE, Fraser CG, Halloran SP, Young GP. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver 2014;8:117–30.10.5009/gnl.2014.8.2.117Search in Google Scholar
8. McDonald PJ, Digby J, Innes C, Strachan JA, Carey FA, Steele RJ, et al. Low faecal haemoglobin concentration potentially rules out significant colorectal disease. Colorectal Dis 2013;15:e151–9.10.1111/codi.12087Search in Google Scholar
9. Cubiella J, Salve M, Díaz-Ondina M, Alves MT, Iglesias F, Sánchez E, et al. Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria. Colorectal Dis 2014;16:O273–82.10.1111/codi.12569Search in Google Scholar
10. Kaul A, Shah A, Magill FH, Hawkins SA, Skaife P. Immunological faecal occult blood testing: a discriminatory test to identify colorectal cancer in symptomatic patients. Int J Surg 2013;11:329–31.10.1016/j.ijsu.2013.02.013Search in Google Scholar
12. GMEC Evaluation Team; Evaluation of quantitative faecal immunochemical tests for haemoglobin, 2013. Available at http://www.worldendo.org/assets/downloads/pdf/activities/fit_reports/gmec_fit_evaluation_report.pdf. Accessed: 31 August 2015.Search in Google Scholar
13. Fujimura K, Kurita Y, Nishimura E, Yamaguchi J, Mori S, Satho H. Comparison study of automated immunochemical fecal occult blood test analyser performance. J Clin Lab Instrum Reagents 2013;36:679–85.Search in Google Scholar
15. Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, et al. Advances in fecal occult blood tests: the FIT revolution. Dig Dis Sci 2015;60:609–22.10.1007/s10620-014-3445-3Search in Google Scholar
16. Digby J, Fraser CG, Carey FA, McDonald PJ, Strachan JA, Diament RH, et al. Faecal haemoglobin concentration is related to severity of colorectal neoplasia. J Clin Pathol 2013;66:415–9.10.1136/jclinpath-2013-201445Search in Google Scholar
17. Liao CS, Lin YM, Chang HC, Chen YH, Chong LW, Chen CH, et al. Application of quantitative estimates of fecal hemoglobin concentration for risk prediction of colorectal neoplasia. World J Gastroenterol 2013;19:8366–72.10.3748/wjg.v19.i45.8366Search in Google Scholar
18. Garcia M, Milà N, Binefa G, Benito L, Gonzalo N, Moreno V. Fecal hemoglobin concentration as a measure of risk to tailor colorectal cancer screening: are we there yet? Eur J Cancer Prev 2015;24:321–7.10.1097/CEJ.0000000000000090Search in Google Scholar
19. Auge JM, Pellise M, Escudero JM, Hernandez C, Andreu M, Grau J, et al. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program. Gastroenterology 2014;147:628–36.10.1053/j.gastro.2014.06.008Search in Google Scholar
20. Fraser CG, Rubeca T, Rapi S, Chen LS, Chen HH. Faecal haemoglobin concentrations vary with sex and age, but data are not transferable across geography for colorectal cancer screening. Clin Chem Lab Med 2014;52:1211–6.10.1515/cclm-2014-0115Search in Google Scholar
21. Symonds EL, Osborne J, Cole SR, Bampton P, Fraser R, Young GP. Gender differences in faecal haemoglobin concentration. J Med Screen 2015; Jul 20 [Epub ahead of print]10.1177/0969141315597018Search in Google Scholar
22. Mowat C, Digby J, Strachan JA, Wilson R, Carey FA, Fraser CG, et al. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut 2015; Aug 20 [Epub ahead of print]10.1136/gutjnl-2015-309579Search in Google Scholar
23. Auge JM, Fraser CG, Rodriguez C, Roset A, Lopez-Ceron M, Grau J, et al. Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients. Clin Chem Lab Med 2016;54:125–32.10.1515/cclm-2015-0388Search in Google Scholar
25. Kok L, Elias SG, Witteman BJ, Goedhard JG, Muris JW, Moons KG, et al. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision rule for Abdominal complaints in primary caRe (CEDAR) study. Clin Chem 2012;58:89–98.10.1373/clinchem.2011.177980Search in Google Scholar
26. Rodríguez-Alonso L, Rodríguez-Moranta F, Ruiz-Cerulla A, Lobatón T, Arajol C, Binefa G, et al. An urgent referral strategy for symptomatic patients with suspected colorectal cancer based on a quantitative immunochemical faecal occult blood test. Dig Liver Dis 2015;47:797–804.10.1016/j.dld.2015.05.004Search in Google Scholar
27. Wu D, Luo HQ, Zhou WX, Qian JM, Li JN. The performance of three-sample qualitative immunochemical fecal test to detect colorectal adenoma and cancer in gastrointestinal outpatients: an observational study. PLoS One 2014;9:e106648.10.1371/journal.pone.0106648Search in Google Scholar
28. Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg SJ, Mulder CJ, et al. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. Br Med J 2010;340:c1269.10.1136/bmj.c1269Search in Google Scholar
©2016 by De Gruyter